Loading
Nanoparticle-based Drug Delivery / Nanoplatforms for Cancer Theranostics · Journal article
Pharmacia · August 17, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of inorganic nanoparticle-based drug delivery systems published 2020–2025, synthesizing literature on magnetic nanoparticles, metal–organic frameworks, and siRNA carriers for cancer therapy. The source identifies potential but reports no original empirical data, efficacy measures, or human clinical outcomes; it concludes that optimizing synthesis while minimizing cellular toxicity is needed for future translational work.
Narrative review. Peer-reviewed original research and review articles on inorganic nanoparticle drug delivery systems in cancer therapy.. Intervention: Inorganic nanoparticle-based drug delivery systems, including magnetic nanoparticles, metal–organic frameworks, and siRNA carriers.
Magnetic nanoparticles, metal–organic frameworks, and siRNA-carrying inorganic nanoparticles are highlighted as innovative strategies for enhancing antitumor treatment Nanomedicine has made significant progress in inorganic nanoparticle-based drug delivery systems over the past decade
Source does not report human safety or toxicity data
This review does not provide evidence-based guidance for clinical practice. Clinicians and researchers should note that inorganic nanoparticle systems remain in preclinical and early development stages; translational potential is acknowledged but not yet demonstrated in human trials.
This is a narrative review synthesizing literature on nanoparticle drug delivery mechanisms and applications, raising questions about translational potential rather than testing a clinical hypothesis with empirical data.
As stated by the source record.
This review does not provide evidence-based guidance for clinical practice. Clinicians and researchers should note that inorganic nanoparticle systems remain in preclinical and early development stages; translational potential is acknowledged but not yet demonstrated in human trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Aim: Over the past decade, nanomedicine has made significant progress in the development of inorganic nanoparticle (iNP)-based drug delivery systems (DDSs). The aim of this narrative review is to summarize the most recent developments in iNP systems, emphasize their advantages as DDSs, and provide detailed commentary on their impact on human health. A systematic search was performed in the PubMed, Scopus, and Web of Science databases for peer-reviewed original research and review articles published between 2020 and 2025. Relevant scientific data on innovative applications of iNPs in cancer therapy were reviewed. The enormous potential of magnetic nanoparticles (NPs), metal–organic frameworks (MOFs), and iNPs used as carriers of small interfering RNAs (siRNAs) as innovative strategies for enhancing antitumor treatment is highlighted. Conclusion: Continuous progress in research strategies for synthesizing iNPs with optimal properties while minimizing adverse effects on living cells is a prerequisite for even greater translational potential of iNP-based DDSs.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.